JPMorgan Upgrades Novartis to "Overweight" (NVS)

JPMorgan Upgrades Novartis to “Overweight” (NVS)


JPMorgan reported on Friday that it has upgraded healthcare product giant, Novartis AG (NVS).

The firm has increased its rating for the company from “Neutral” to “Overweight.”

An analyst from the firm commented, “we upgrade Novartis to overweight from Neutral with a new 18 month price target of Sfr 78 assuming the stock can approach a sector multiple by mid 2014 which reflects FCF growth beyond 2019 of just below 1%.”

Novartis shares were up 56 cents, or 0.81% during Friday morning trading. The stock has increased 28% in the past year.

The Bottom Line
Shares of Novartis AG (NVS) have a 3.64% yield, based on Friday morning’s price of $69.57.

Novartis AG (NVS) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today